Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionBispecific antibody generated via the dock and lock (DNL) method that comprises a single chain variable fragment that binds to CD19 on B cells and CD3 on T cells
Molecular Target CD3 ; CD19
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationLymphoma
Indication DetailsTreat lymphoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today